Company Encyclopedia
View More
name
Theravance BioPharma
TBPH.US
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc.
4.514 T
TBPH.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking26/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE14.03%B
    • Profit Margin36.53%A
    • Gross Margin59.42%A
  • Growth ScoreA
    • Revenue YoY27.12%A
    • Net Profit YoY159.40%A
    • Total Assets YoY16.67%A
    • Net Assets YoY25.33%A
  • Cash ScoreB
    • Cash Flow Margin273.74%C
    • OCF YoY27.12%A
  • Operating ScoreD
    • Turnover0.21D
  • Debt ScoreC
    • Gearing Ratio43.99%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Dir Broshy Sells 29,501 ($590K) Of Theravance Biopharma Inc [TBPH]

    Broshy Eran Director of Theravance Biopharma Inc [TBPH] filed a Form 4 on December 1, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/26/25TransactionPlanned Sale(1) Shares29,501Price$20.00Value$590,020Ending Holdings: 44,703 - Direct(1) Executed pursuant to a prearranged trading plan (10b5-1).For a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    TBPH
    -1.01%
    Reuters·
    US
    TBPH
    -1.01%

    Theravance Biopharma Director Eran Broshy Reports Disposal of Common Shares

    Theravance Biopharma Director Eran Broshy has reported the disposal of common shares. The filing is available via EDGAR, the SEC's system. This AI-generated news is for informational purposes only and not financial advice. Theravance Biopharma is responsible for the original content.

    Reuters·
    US
    TBPH
    -1.01%
    Reuters·
    US
    TBPH
    -1.01%

    CFO Sawaf Surrenders 18,627 Of Theravance Biopharma Inc [TBPH]

    Theravance Biopharma Inc's CFO, Sawaf Aziz, surrendered 18,627 shares back to the company to cover option exercise costs and/or tax liabilities, as disclosed in a Form 4 filed with the SEC on November 24, 2025. The transaction was valued at $333,423, with an ending holding of 336,795 shares directly.

    Reuters·
    US
    TBPH
    -1.01%
    Reuters·
    US
    TBPH
    -1.01%

    VP Miller Surrenders 6,989 Of Theravance Biopharma Inc [TBPH]

    VP Miller of Theravance Biopharma Inc surrendered 6,989 shares back to the company to cover option exercise costs and tax liabilities. The transaction was disclosed in a Form 4 filed with the SEC on November 24, 2025. The shares were valued at $125,103, with a price of $17.90 per share. Miller's ending holdings are 201,012 shares directly.

    Reuters·
    US
    TBPH
    -1.01%
    Reuters·
    US
    TBPH
    -1.01%

    VP Grimaud Surrenders 19,024 Of Theravance Biopharma Inc [TBPH]

    Grimaud Brett A, Vice President of Theravance Biopharma Inc [TBPH], surrendered 19,024 shares at $17.90 each, valued at $340,530, to cover option exercise costs and/or tax liabilities. His ending holdings are 355,282 shares. This was disclosed in a Form 4 filed with the SEC on November 24, 2025.

    Reuters·
    US
    TBPH
    -1.01%
    Reuters·
    US
    TBPH
    -1.01%
    © 2025 Longbridge｜Disclaimer